Prof. Perry M. Elliott
Prof. Perry M. Elliott (H-index 100) is Professor of Cardiovascular Medicine at University College London (UCL) and a Senior Investigator of the UK National Institute for Health Research (NIHR). He is director of the UCL Centre for Heart Muscle Disease, Head of Clinical Research at the Institute of Cardiovascular Science UCL and a consultant cardiologist in the Centre for Inherited Cardiovascular Disease at the Bart’s Heart Centre, St. Bartholomew’s Hospital London, UK. He studied medicine at St. Thomas’s Hospital Medical School, London. After qualifying in 1987 he trained in general medicine, gaining membership of the Royal College of Physicians in 1991, and completed his general cardiology training at St. George’s Hospital Medical School, London. He was appointed as Senior Lecturer first at St. George’s Hospital in 1999 and then at UCL in 2003. He was promoted to Reader in Inherited Cardiac Disease in 2005 and became a full Professor at UCL in 2012.
He was elected as a Fellow of the European Society of Cardiology (ESC) in 2005, is Chairman of the ESC Heart Academy, past Chairman of the ESC Working Group on Myocardial and Pericardial Diseases (2010–2012) and the Executive Committee for the European Outcomes Research Programme registry on cardiomyopathies, chair of the ESC Guideline Task Force on Hypertrophic Cardiomyopathy, member of the Congress Programme Committee 2018-2020 and a member of the ESC Managerial Council 2018-2020. He is cardiovascular lead for the North Thames NHS Genomic Medicine Centre and President of Cardiomyopathy UK, Europe’s foremost charity for patients with heart muscle disease. From 2009 to 2013, he was Deputy Editor of The Heart Journal and is currently Deputy Editor for the International Journal of Cardiology.
Over the past 25 years, Prof. Elliott has established an international reputation in the field of heart muscle disease, authoring more than 380 peer-reviewed papers on the subject. He develops diagnostic standards, risk stratification tools and clinical service models based on some of Europe’s largest inherited heart disease cohorts, fostering industry collaborations in sequence interpretation, therapeutic trials and multicentre research partnerships.